#stayhome Maintain the distance, wash your hands, and follow instructions from the health authorities.
RSS   Newsletter   Contact   Advertise with us

Endo International Q2 revenues $700 million

Share on Twitter Share on LinkedIn
Christian Fernsby ▼ | August 6, 2019
Endo International reported second-quarter 2019 financial results.
Endo International
Endo International   Reported net loss from continuing operations was $98 million
Highlights:

Revenues of $700 million, a decrease of 2 percent compared to second-quarter 2018 revenues of $715 million.

Branded Pharmaceuticals - Specialty Products revenues increased 17 percent to

124 million compared to second-quarter 2018 revenues of $106 million. Sterile Injectables revenues increased 12 percent to $244 million compared to second-quarter 2018 revenues of $218 million.

Reported net loss from continuing operations of $98 million compared to second-quarter 2018 reported net loss from continuing operations of $52 million.

Reported diluted loss per share from continuing operations of $0.43 compared to second-quarter 2018 reported diluted loss per share from continuing operations of $0.23.

Adjusted income from continuing operations of $120 million compared to second-quarter 2018 adjusted income from continuing operations of $172 million.

Adjusted diluted earnings per share from continuing operations of $0.52 compared to second-quarter 2018 adjusted diluted earnings per share from continuing operations of $0.76.

Adjusted EBITDA of $307 million compared to second-quarter 2018 adjusted EBITDA of $351 million.


 

MORE INSIDE POST